Reviews on Recent Clinical Trials

Alberto Zaniboni  
Oncologia Medica, Fondazione Poliambulanza
Brescia
Italy

Back

Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review

Author(s): Tolia Maria, Zygogianni Anna, Kouvaris John R., Tsoukalas Nikolaos, Kokakis Ioannis, Kyrgias George, Mystakidou Kyriaki and Kouloulias Vasileios

Affiliation: 76 Vassilissis Sofias Avenue, 115 28, Athens, Greece.

Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.

Abstract:

Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.

Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.

Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.

Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 9
ISSUE: 1
Page: [31 - 36]
Pages: 6
DOI: 10.2174/1574887109666140423123845